Kiniksa Pharmaceuticals Says ARCALYST (rilonacept) 2023 Net Product Revenue Grew ~90% YoY To $233.1M; Sees ARCALYST 2024 Net Product Revenue Of $360M-$380M
Portfolio Pulse from Benzinga Newsdesk
Kiniksa Pharmaceuticals reported that its ARCALYST (rilonacept) net product revenue increased by approximately 90% year-over-year to $233.1 million in 2023. The company also forecasts ARCALYST's net product revenue for 2024 to be between $360 million and $380 million.
January 04, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kiniksa Pharmaceuticals' ARCALYST revenue surged by 90% in 2023, and the company anticipates further growth in 2024, estimating revenues of $360M-$380M.
The significant year-over-year revenue growth for ARCALYST is a strong indicator of the product's market acceptance and sales performance. The positive outlook for 2024 suggests continued growth, which is likely to be viewed favorably by investors and could lead to a short-term increase in Kiniksa Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100